Publisher details
Available items(s) from this publisher (1129)
Add the result to your basket Make a suggestion Refine your search Apply to external sources
A quadrivalent vaccine against serogroup B meningococcal disease / Germaine Hanquet / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2014)
A quadrivalent vaccine against serogroup B meningococcal disease : a cost-effectiveness study [printed text] / Germaine Hanquet, Author ; Hannah Christensen, Author ; Agnew Emily, Author ; Caroline Trotter, Author ; Jo Robays, Author ; Cécile Dubois , Author ; Stephan Devriese , Author ; Stefaan Van de Sande , Author ; Nancy Thiry, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2014 . - 141 p. : ill., ; A4. - (KCE Reports. Health Technology Assessment (HTA); 231C) .
ISSN : D/2014/10.273/77 : € 0,00
Study 2012-23 HTA Meningococ Vaccine B
Languages : English (eng)
Descriptors: Indexation
2012-23 ; Adolescent ; Cost-Benefit Analysis ; Costs and Cost Analysis ; Infant ; Meningococcal Vaccines ; Neisseria meningitidis, Serogroup B ; R231
Classification
WC 245 Meningococcal infectionsContents note: LIST OF FIGURES 5 -- LIST OF TABLES .8 -- LIST OF ABBREVIATIONS .11 -- SCIENTIFIC REPORT 13 -- 1 BACKGROUND 13 -- 1.1 INVASIVE MENINGOCOCCAL DISEASE .13 -- 1.2 MENINGOCOCCAL CARRIAGE 14 -- 1.3 VACCINES AGAINST MENINGOCOCCAL DISEASE 14 -- 1.4 RESEARCH QUESTIONS .14 -- 2 BELGIAN DATABASES AND MATCHING 16 -- 2.1 DATABASE SOURCES 16 -- 2.2 MATCHING OF THE MZG-RHM AND NRC DATABASES 17 -- 3 BURDEN OF SEROGROUP B MENINGOCOCCAL DISEASE 18 -- 3.1 MEDICAL BURDEN 18 -- 3.1.1 Incidence and age distribution 18 -- 3.1.2 Temporal trends 19 -- 3.1.3 Distribution of vaccine-preventable strains .21 -- 3.1.4 Regional variations 21 -- 3.1.5 Clinical picture 23 -- 3.1.6 Mortality and case fatality ratio .23 -- 3.1.7 Long-term complications and sequelae 24 -- 3.2 QUALITY OF LIFE BURDEN 28 -- 3.2.1 Methods.28 -- 3.2.2 Results 28 -- 4 VACCINE EFFICACY AND SAFETY 34 -- 4.1 VACCINE EFFICACY AGAINST DISEASE 34 -- 4.1.1 SBA responses against the four vaccine components .34 -- 4.1.2 Persistence of hSBA responses 36 -- 4.1.3 Correlation between SBA and clinical protection .37 -- 4.1.4 Predicted strain coverage of the 4CMenB vaccine .38 -- 4.1.5 Relation between MATS and SBA 39 -- 4.2 VACCINE EFFICACY AGAINST CARRIAGE 39 -- 4.3 VACCINE ADVERSE EVENTS 40 -- 5 ANALYTICAL CHOICES FOR THE ECONOMIC EVALUATION OF 4CMENB IN BELGIUM .42 -- 5.1 MODELS STRUCTURE 42 -- 5.1.1 Model structure - details common to both models 42 -- 5.1.2 Model structure – static specific details 42 -- 5.1.3 Model structure – dynamic specific details .42 -- 5.2 OUTCOMES AND COMPARATOR 44 -- 5.3 PERSPECTIVE 44 -- 5.4 TIME HORIZON 44 -- 5.5 DISCOUNTING 44 -- 5.6 DEMOGRAPHICS 44 -- 5.7 INTERPRETATION OF THE COST-EFFECTIVENESS RESULTS .45 -- 6 INPUT FOR THE MODELS45 -- 6.1 VACCINATION STRATEGIES .45 -- 6.1.1 Vaccination schedules 45 -- 6.1.2 Vaccine uptakes to be simulated .47 -- 6.2 CLINICAL / EPIDEMIOLOGICAL PARAMETERS .48 -- 6.2.1 Age-specific incidence rates 48 -- 6.2.2 4CMenB preventable disease 48 -- 6.2.3 Case fatality ratio .49 -- 6.2.4 Frequency of sequelae 49 -- 6.3 VACCINE-RELATED PARAMETERS 50 -- 6.3.1 Vaccine efficacy 50 -- 6.3.2 Vaccine waning rate 50 -- 6.3.3 Efficacy against transmission .52 -- 6.3.4 Vaccine side-effects 52 -- 6.4 QUALITY OF LIFE 53 -- 6.5 ECONOMIC PARAMETERS .54 -- 6.5.1 Acute care hospitalization costs 54 -- 6.5.2 Cost of follow-up care for those with no sequelae 59 -- 6.5.3 Cost of follow-up care for those with sequelae .59 -- 6.5.4 Cost of public health interventions targeting contacts of a case 64 -- 6.5.5 Vaccination programme costs 65 -- 6.6 PARAMETERS SPECIFIC TO THE DYNAMIC MODEL 70 -- 6.6.1 Meningococcal carriage 70 -- 6.6.2 Mixing patterns 70 -- 6.7 UNCERTAINTY 70 -- 6.7.1 Probabilistic sensitivity analysis in the static model 70 -- 6.7.2 Scenario analyses 73 -- 6.8 SUMMARY OF INPUT PARAMETERS VALUES 76 -- 7 MODEL VALIDATION 80 -- 7.1 POPULATION 80 -- 7.2 CASES PREDICTED .80 -- 8 RESULTS FROM THE STATIC MODEL 81 -- 8.1 CLINICAL IMPACT OF DIFFERENT VACCINATION POLICIES 81 -- 8.2 COST-EFFECTIVENESS OF DIFFERENT VACCINATION POLICIES .81 -- 8.3 FINANCIAL IMPACT OF DIFFERENT VACCINATION POLICIES 85 -- 8.4 SCENARIO ANALYSIS 86 -- 8.5 ANALYSIS OF COVARIANCE .89 -- 9 RESULTS FROM THE DYNAMIC MODEL 90 -- 9.1 CLINICAL IMPACT OF DIFFERENT VACCINATION STRATEGIES 90 -- 9.2 COST-EFFECTIVENESS OF DIFFERENT VACCINATION STRATEGIES .96 -- 9.3 SCENARIO ANALYSIS 97 -- 10 USE OF 4CMENB IN OUTBREAKS OR CLUSTERS 102 -- 11 DISCUSSION 103 -- 11.1 4CMENB VACCINATION 103 -- 11.1.1 If 4CMenB has no effect on transmission (base case) 103 -- 11.1.2 If 4CMenB may prevent transmission 104 -- 11.1.3 Use of 4CMenB in control of clusters and outbreaks 105 -- 11.2 STRENGTHS AND LIMITATIONS 106 -- 11.3 IMPLICATIONS FOR PRACTICE 108 -- 11.4 FUTURE PERSPECTIVE 109 -- 12 CONCLUSIONS 110 -- APPENDICES 111 -- APPENDIX 1. REVIEW OF THE LITERATURE ON QUALITY OF LIFE 111 -- APPENDIX 1.1. SEARCH STRATEGIES 111 -- APPENDIX 1.2. SELECTION OF THE STUDIES 114 -- APPENDIX 2. ICD-9-CM CODES 115 -- APPENDIX 3. COSTS OF IMD PATIENTS WITH SEQUELAE 116 -- APPENDIX 3.1. SEROGROUP B 116 -- APPENDIX 3.2. ALL SEROGROUPS 119 -- APPENDIX 4. INFANT VACCINE CALENDAR IN BELGIUM 122 -- APPENDIX 5. DYNAMIC MODEL EQUATIONS, POPULATION MIXING AND RISK OF DISEASE GIVEN INFECTION 123 -- APPENDIX 5.1. TRANSMISSION DYNAMIC MODEL EQUATIONS 123 -- APPENDIX 5.2. MIXING PATTERNS – SIMPLE PREFERENTIAL MIXING 123 -- APPENDIX 5.3. TRANSMISSION DYNAMIC MODEL PARAMETER FITTING 124 -- APPENDIX 6. COST OF PUBLIC HEALTH INTERVENTIONS FOR CONTACTS OF AN IMD CASE 126 -- APPENDIX 7. INCREMENTAL COST-EFFECTIVENESS ANALYSIS, DYNAMIC MODEL WITH 0% VACCINE EFFICACY AGAINST CARRIAGE 127 -- APPENDIX 8. MONTE CARLO SIMULATION RESULTS ON THE COST-EFFECTIVENESS PLANE FOR THE SCENARIO ANALYSES OF THE STATIC MODEL 128 -- REFERENCES 133 Link for e-copy: http://doi.org/10.57598/R231C Format of e-copy: PDF (2,7 Mb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3453 A quadrivalent vaccine against serogroup B meningococcal disease / Germaine Hanquet / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2014)
A quadrivalent vaccine against serogroup B meningococcal disease : a cost-effectiveness study - Supplement [printed text] / Germaine Hanquet, Author ; Hannah Christensen, Author ; Agnew Emily, Author ; Caroline Trotter, Author ; Jo Robays, Author ; Cécile Dubois , Author ; Stephan Devriese , Author ; Stefaan Van de Sande , Author ; Nancy Thiry, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2014 . - 59 p. : ill., ; A4. - (KCE Reports. Health Technology Assessment (HTA); 231S) .
ISSN : D/2014/10.273/78 : € 0,00
Study 2012-23 HTA Meningococ Vaccine B
Languages : English (eng)
Descriptors: Indexation
2012-23 ; Adolescent ; Cost-Benefit Analysis ; Costs and Cost Analysis ; Infant ; Meningococcal Vaccines ; Neisseria meningitidis, Serogroup B ; R231
Classification
WC 245 Meningococcal infectionsContents note: A. Summary 2 -- B. Introduction 3 -- C. Models, parameters and data sources 3 -- D. Model validation 13 -- E. Results.14 -- E. Strengths and limitations 39 -- F. Conclusions 39 -- Appendix 1. Dynamic model equations, population mixing and estimating the risk of disease given infection 41 -- Appendix 2. Cost‐effectiveness planes for cohort model scenarios.45 -- References 58 Link for e-copy: http://doi.org/10.57598/R231S Format of e-copy: PDF (1,5 Mb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3455 Copies(0)
Status No copy A quadrivalent vaccine against serogroup B meningococcal disease / Germaine Hanquet / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2014)
A quadrivalent vaccine against serogroup B meningococcal disease : a cost-effectiveness study - Synthesis [printed text] / Germaine Hanquet, Author ; Hannah Christensen, Author ; Agnew Emily, Author ; Caroline Trotter, Author ; Jo Robays, Author ; Cécile Dubois , Author ; Stephan Devriese , Author ; Stefaan Van de Sande , Author ; Nancy Thiry, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2014 . - 35 p. : ill., ; A4. - (KCE Reports. Health Technology Assessment (HTA); 231Cs) .
ISSN : D/2014/10.273/76 : € 0,00
Study 2012-23 HTA Meningococ Vaccine B
Languages : English (eng)
Descriptors: Indexation
2012-23 ; Adolescent ; Cost-Benefit Analysis ; Costs and Cost Analysis ; Infant ; Meningococcal Vaccines ; Neisseria meningitidis, Serogroup B ; R231
Classification
WC 245 Meningococcal infectionsContents note: FOREWORD 1 -- ABSTRACT 2 -- SYNTHESIS 4 -- 1. MENINGOCOCCAL DISEASE AND VACCINES 6 -- INVASIVE MENINGOCOCCAL DISEASE AND SEROGROUP B 6 -- THE 4CMENB VACCINE 7 -- RESEARCH QUESTION 8 -- 2. MODELS AND ECONOMIC EVALUATION – METHODS 9 -- MODELS STRUCTURE 9 -- 2.1.1. Details common to both models 9 -- 2.1.2. Static model specific details 9 -- 2.1.3. Dynamic model specific details 9 -- CLINICAL IMPACT AND ECONOMIC EVALUATION 10 -- 3. INPUT PARAMETERS 11 -- EPIDEMIOLOGICAL AND CLINICAL PARAMETERS 11 -- VACCINATION PARAMETERS 12 -- COST PARAMETERS 13 -- QUALITY OF LIFE 13 -- PARAMETERS COMBINED FOR BEST AND WORST CASE SCENARIOS 14 -- 4. CLINICAL IMPACT AND COST-EFFECTIVENESS OF 4CMENB VACCINATION 19 -- CURRENT BURDEN OF SEROGROUP B INVASIVE MENINGOCOCCAL DISEASE 19 -- 4CMENB VACCINATION – IF NO EFFECT ON CARRIAGE 19 -- 4.2.1. Infant vaccination 19 -- 4.2.2. Adolescent vaccination 20 -- 4CMENB VACCINATION – IF EFFECT ON CARRIAGE 20 -- 4.3.1. Infant vaccination 20 -- 4.3.2. Adolescent vaccination 20 -- 5. DISCUSSION 22 -- 5.1 4CMENB VACCINATION 22 -- 5.1.1. If 4CMenB has no effect on carriage (base case) 22 -- 5.1.2. If 4CMenB has an effect on carriage 23 -- 5.1.3. Use of 4CMenB in control of clusters and outbreaks 24 -- STRENGTHS AND LIMITATIONS OF THIS ANALYSIS 24 -- IMPLICATIONS FOR PRACTICE 26 -- FUTURE PERSPECTIVES 27 -- 6. CONCLUSIONS 27 -- RECOMMENDATIONS 29 -- REFERENCES 31 Link for e-copy: http://doi.org/10.57598/R231CS Format of e-copy: PDF (611 Kb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3454 Copies(0)
Status No copy Qualité et organisation des soins du diabète de type 2 / Chantal Mathieu / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2006)
Copies(0)
Status No copy Quality and organisation of type 2 diabetes care / Chantal Mathieu / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2006)
Quality and organisation of type 2 diabetes care : Appendices [printed text] / Chantal Mathieu, Author ; Delphine Thimus, Author ; Dominique Pestiaux, Author ; Luk Van Eygen, Author ; Geert Goderis, Author ; Swinnen, Sarah, Author ; Liesbeth Borgermans, Author ; Jan Heyrman, Author ; Kristien Dirven, Author ; Johan Wens, Author ; Dominique Paulus , Author ; Gert Peeters, Author ; Dirk Ramaekers, Author ; Jan De Maeseneer, Author ; Paul Van Royen, Author ; Luc Feyen, Author ; Frank Nobels, Author ; Patricia Sunaert, Author ; Marc Vanandruel, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2006 . - 423 p. : ill. ; 30 cm.. - (KCE Reports. Good Clinical Practice (GCP); 27S) .
ISSN : D/2006/10.273/09 : 0 €
2004-10
Languages : English (eng)
Descriptors: Classification
WK 810 Diabetes mellitus
Indexation
2004-10 ; Diabetes Mellitus, Type 2 ; Health Services Research ; Organizations ; Quality Indicators, Health Care ; R27Link for e-copy: https://doi.org/10.57598/R27S Format of e-copy: Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=697 Copies(0)
Status No copy Quality Assurance of rectal cancer diagnosis and treatment – phase 3 / Els Goetghebeur / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)
PermalinkQuality Assurance of rectal cancer diagnosis and treatment – phase 3 / Els Goetghebeur / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)
PermalinkQuality Assurance of rectal cancer diagnosis and treatment – phase 3 / Els Goetghebeur / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)
PermalinkQuality criteria for training settings in postgraduate medical education / Roy Remmen / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2010)
PermalinkQuality criteria for training settings in postgraduate medical education – Supplement / Roy Remmen / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2010)
PermalinkQuality improvement in general practice in Belgium / Roy Remmen / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2008)
PermalinkQuality indicators for the management of epithelial ovarian cancer / Isabelle Savoye / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2022)
PermalinkQuality indicators for the management of epithelial ovarian cancer / Isabelle Savoye / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2022)
PermalinkQuality indicators for the management of head and neck squamous cell carcinoma / Roos Leroy / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2019)
PermalinkQuality indicators for the management of head and neck squamous cell carcinoma / Roos Leroy / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2019)
Permalink
GRID: https://grid.ac/institutes/grid.414403.6
ISN: http://isni.org/isni/0000000406298370